



- (51) **International Patent Classification:**
A61K 38/11 (2006.01) *A61P 15/12* (2006.01)
- (21) **International Application Number:**
PCT/EP2012/056813
- (22) **International Filing Date:**
13 April 2012 (13.04.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
1150324-0 14 April 2011 (14.04.2011) SE
61/475,471 14 April 2011 (14.04.2011) US
- (71) **Applicant (for all designated States except US):** PEP-
TONIC MEDICAL AB [SE/SE]; Honnörsgatan 16, S-
352 36 Växjö (SE).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** UVNÄS-MOBERG,
Kerstin [SE/SE]; Ynglingavägen 11, S-182 62 Djursholm
(SE). CARLSSON, Anders [SE/SE]; Hornsbergs Strand
49, S-112 16 Stockholm (SE).
- (74) **Agent:** VALEA AB; Box 7086, S-103 87 Stockholm (SE).

- (81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** PHARMACEUTICAL COMPOSITION

(57) **Abstract:** The present invention relates to a novel pharmaceutical composition comprising oxytocin and/or one or more frag-
ment(s) and/or variant(s) thereof and at least one non-ionic cellulose ether, such as hydroxypropylmethylcellulose, said pharmaceu-
tical composition having a low pH. The present pharmaceutical composition has been shown to provide an exceptionally suitable en-
vironment for oxytocin, as the stability thereof has increased significantly as compared to previous compositions with this molecule.
The pharmaceutical composition according to the invention can be used for medical purposes, such as in the treatment of climacteric
disorders.

